What is Kimmtrak?
Kimmtrak (generic name: tebentafusp) is a cancer medicine that targets a specific protein on cancer cells. It is used to treat certain patients with advanced melanoma that has a particular genetic feature (HLA-A*02:01 positive) [1].
What cancer does Kimmtrak treat?
Kimmtrak is indicated for patients with advanced uveal melanoma or metastatic melanoma with the relevant HLA-A*02:01 status, depending on the specific indication approved in the product labeling [1].
Who is eligible to receive it (HLA-A*02:01 testing)?
The key eligibility factor is whether a patient tests positive for HLA-A*02:01. This genetic status is required before starting treatment because Kimmtrak works only in patients whose immune system can present the target that the drug recognizes [1].
How is Kimmtrak given?
Kimmtrak is given as an infusion through a vein, typically on a schedule that starts with closely monitored dosing. The first doses often require extra monitoring because infusion-related reactions can occur [1].
What side effects do patients commonly ask about?
Patients and clinicians often ask about infusion-related reactions and skin or liver-related lab changes. Kimmtrak can also cause fatigue and other treatment-related effects, depending on the patient and dose [1].
Where can I check the official prescribing information?
For dosing, eligibility criteria, warnings, and the full list of side effects, the most reliable source is the official FDA prescribing information for Kimmtrak [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212151